- Home
- CRVS vs IIIV Comparison
CRVS vs IIIV Comparison
Compare CRVS & IIIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- IIIV
- Stock Information
- Founded
- CRVS 2014
- IIIV 2012
- Country
- CRVS United States
- IIIV United States
- Employees
- CRVS N/A
- IIIV N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- IIIV EDP Services
- Sector
- CRVS Health Care
- IIIV Technology
- Exchange
- CRVS Nasdaq
- IIIV Nasdaq
- Market Cap
- CRVS 516.0M
- IIIV 562.5M
- IPO Year
- CRVS 2016
- IIIV 2018
- Fundamental
- Price
- CRVS $5.22
- IIIV $24.18
- Analyst Decision
- CRVS Strong Buy
- IIIV Buy
- Analyst Count
- CRVS 5
- IIIV 7
- Target Price
- CRVS $12.38
- IIIV $27.14
- AVG Volume (30 Days)
- CRVS 1.6M
- IIIV 279.9K
- Earning Date
- CRVS 11-12-2024
- IIIV 02-06-2025
- Dividend Yield
- CRVS N/A
- IIIV N/A
- EPS Growth
- CRVS N/A
- IIIV N/A
- EPS
- CRVS N/A
- IIIV 4.84
- Revenue
- CRVS N/A
- IIIV $229,923,000.00
- Revenue This Year
- CRVS N/A
- IIIV $11.47
- Revenue Next Year
- CRVS N/A
- IIIV $8.50
- P/E Ratio
- CRVS N/A
- IIIV $5.00
- Revenue Growth
- CRVS N/A
- IIIV 1.41
- 52 Week Low
- CRVS $1.30
- IIIV $17.54
- 52 Week High
- CRVS $10.00
- IIIV $26.66
- Technical
- Relative Strength Index (RSI)
- CRVS 41.23
- IIIV 57.03
- Support Level
- CRVS $4.60
- IIIV $23.50
- Resistance Level
- CRVS $6.47
- IIIV $24.21
- Average True Range (ATR)
- CRVS 0.39
- IIIV 0.61
- MACD
- CRVS 0.06
- IIIV 0.07
- Stochastic Oscillator
- CRVS 33.16
- IIIV 96.77
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About IIIV i3 Verticals Inc.
i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Public Sector and Healthcare. The company generates maximum revenue from the Public Sector segment.